6533b855fe1ef96bd12b12c7

RESEARCH PRODUCT

Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome

Dimitri P. MikhailidisGiuseppe MontaltoMilan ObradovicEsma R. IsenovicMilica Labudovic-borovicDragana NikolicRizzo ManfrediAli A. Rizvi

subject

Riskmedicine.medical_specialtyOrganic Cation Transport ProteinsOrganic anion transporter 1Uric acid pre-hypertension metabolic sindrome cardiovascular metabolismGlucose Transport Proteins FacilitativeOrganic Anion TransportersHyperuricemia030204 cardiovascular system & hematologymetabolic syndromePrehypertensionPrehypertension03 medical and health scienceschemistry.chemical_compound0302 clinical medicineuric acidInternal medicinemedicineAnimalsHumanspre-hypertensionHyperuricemiaMetabolic SyndromePharmacologyOrganic cation transport proteinsbiologybusiness.industryMedicine (all)Glucose transporterCardiovascular riskmedicine.diseaseUric AcidMetabolic pathwayMetabolismEndocrinologychemistrybiology.proteinUric acidMetabolic syndromeCardiology and Cardiovascular MedicinebusinessPre-hypertensionmetabolism030217 neurology & neurosurgery

description

In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore, the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or cardiovascular risk factors.

yearjournalcountryeditionlanguage
2014-07-31Current Vascular Pharmacology
https://doi.org/10.2174/1570161111999131205160756